HOME >> MEDICINE >> NEWS
Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial

Copenhagen, Denmark: Eagerly awaited results from the world's first head to head trial between the anti-cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol)[1] have shown that there was a better overall response rate and longer overall survival among breast cancer patients given docetaxel although docetaxel was associated with more severe side effects.

The new results were presented for the first time today (Wednesday 24 September) at ECCO 12 The European Cancer Conference taking place in Copenhagen.

Four hundred and forty nine women with advanced incurable breast cancer who had received previous treatment with an anthracycline-based chemotherapy were randomised into the Phase III trial from multiple centres across the USA between 1994 and 20012. Half were treated with paclitaxel and half were treated with docetaxel.

The trial's principal investigator, Professor Peter Ravdin, associate professor in the Department of Medicine at the University of Texas Health Science Center in San Antonio, told a news briefing that the women treated with docetaxel survived for a median 15.4 months compared with a median 12.7 months for the women who received paclitaxel.

There was an overall response rate of nearly a third among the docetaxel patients compared with a quarter for the paclitaxel patients. The median time before the breast cancer progressed (TTP) was 5.7 months for the docetaxel patients and 3.6 months for the paclitaxel patients. The results for overall survival and for TTP were statistically significantly superior for docetaxel and the overall response rate in favour of docetaxel approached statistical significance.

However, the women who received docetaxel did experience more severe side effects (grade 3/4 toxicities) with higher incidences of neutropenia (reduction in infection-fighting white blood cells), asthenia (loss of strength), infection, oedema (abnormal accumulation of fluid), mouth ulcers and neuromotor and n
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
45-3252-4163
Federation of European Cancer Societies
24-Sep-2003


Page: 1 2

Related medicine news :

1. Good intentions versus bad habits: Why the old ways win out
2. Normal aging versus Alzheimers disease and the potential for prevention
3. Regulatory T cells keep graft-versus-host disease in check
4. Study evaluates Abacavir, Lamivudine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz
5. U-M study finds new target in war against graft-versus-host disease
6. Weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) is safe and effective in patients with advanced lung cancer
7. International breast cancer prevention study launches in the United States and Canada
8. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/13/2018)... SACRAMENTO (PRWEB) , ... September 13, 2018 , ... ... , an organization that operates the largest shelter for women and children experiencing homelessness ... campaign which was developed to keep the red doors of Saint John’s open ...
(Date:9/12/2018)... ... , ... Today, Sterling , a rope and life-safety equipment company, announced ... climb of the Lotus Flower Tower in Canada’s Cirque of the Unclimbables. Although Jim ... the duo decided to persevere and with some assistance from rigger Pat Goodman and ...
(Date:9/12/2018)... ... 13, 2018 , ... Glori Blends will be attending the CBD Expo West ... will include vendors, presentations, panel discussions and a special pavilion for pet line products. ... winning products and assist customers with the best selection for their individual needs. , ...
(Date:9/7/2018)... Calif. (PRWEB) , ... September 07, 2018 , ... ... Positas Community College District , the only OSHA authorized OTI Education Center headquartered ... to assist employees who feel they have experienced retaliation in response to ...
(Date:9/2/2018)... ... September 01, 2018 , ... Women’s ... its leading menu of results-driven aesthetic treatments. HydraFacial is a critically-acclaimed skin ... ingredients to dramatically improve your skin’s tone and texture for a glowing, ...
Breaking Medicine News(10 mins):
(Date:9/12/2018)... ... September 12, 2018 , ... Surgical Theater ... Chicago, IL, from September 19-22. The IT + Revenue Cycle Conference provides Surgical ... empowerment with the use of Precision Virtual Reality™ medical visualization platform. This 360VR ...
(Date:9/7/2018)... ... September 06, 2018 , ... This year, the California Society of ... his presentation of: IDEAL IMPLANT® - Seven-Year Clinical Trial Results at the 68th CSPS ... at the upcoming ASPS (American Society of Plastic Surgeons) meeting in Chicago this fall. ...
(Date:9/1/2018)... ... August 31, 2018 , ... New ... College’s search for a Vice President/ Dean of Academic Affairs. Reporting directly to ... (VP/Dean AA) is the chief academic officer responsible for the faculty and the ...
Breaking Medicine Technology:
Cached News: